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BACKGROUND

Prior studies with the use of a prospective–retrospective design including archival tumor
samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides
the highest level of evidence supporting the clinical validity and usefulness of a biomarker.
METHODS

We performed a prospective trial involving women with hormone-receptor–positive, human
epidermal growth factor receptor type 2 (HER2)–negative, axillary node–negative breast
cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the
greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic
features. A reverse-transcriptase–polymerase-chain-reaction assay of 21 genes was performed on the paraffin-embedded tumor tissue, and the results were used to calculate a
score indicating the risk of breast-cancer recurrence; patients were assigned to receive
endocrine therapy without chemotherapy if they had a recurrence score of 0 to 10, indicating a very low risk of recurrence (on a scale of 0 to 100, with higher scores indicating a
greater risk of recurrence).
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RESULTS

Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence
score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy.
At 5 years, in this patient population, the rate of invasive disease–free survival was
93.8% (95% confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence
of breast cancer at a distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom
from recurrence of breast cancer at a distant or local–regional site was 98.7% (95% CI,
97.9 to 99.2), and the rate of overall survival was 98.0% (95% CI, 97.1 to 98.6).
CONCLUSIONS

Among patients with hormone-receptor–positive, HER2-negative, axillary node–negative
breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable
gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number,
NCT00310180.)
n engl j med 373;21
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reast cancer is the most common
cancer in women worldwide and in the
United States, and it is the leading cause
of death from cancer in women worldwide.1 Prognostic factors for the recurrence of breast cancer
at a distant site regardless of treatment include
clinicopathologic features such as tumor size and
grade and the number of axillary lymph nodes
with metastasis.2 Predictive factors that identify
a benefit from specific therapies include the expression of the estrogen receptor and the progesterone receptor, which identifies patients who
benefit from adjuvant endocrine therapy,3 and
overexpression of the human epidermal growth
factor receptor 2 (HER2) protein (or HER2 gene
amplification),4 which identifies patients who benefit from adjuvant HER2-directed therapy. Adjuvant chemotherapy reduces the risk of recurrence,
even among patients with axillary node–negative
disease who are at lower risk for recurrence.5-7
For contemporary taxane-based or anthracycline-based chemotherapy regimens, proportional
reductions in risk have been shown to be affected
only minimally by age, nodal status, tumor grade,
estrogen-receptor expression, or use of adjuvant
endocrine therapy.8 These findings led a National
Institutes of Health consensus panel in 2001 to
conclude that “adjuvant polychemotherapy . . .
should be recommended to the majority of
women with localized breast cancer regardless
of lymph node, menopausal, or hormone receptor
status.”9 The widespread use of adjuvant chemotherapy has contributed to the declining breastcancer mortality that has been observed in the
United States and other industrialized nations.10
More than 100,000 women in the United
States received a diagnosis of estrogen-receptor–
positive breast cancer associated with negative
axillary lymph nodes in 2014.11 Although approximately 85% of these women may be recurrence-free at 10 years with adjuvant endocrine
therapy alone, the addition of chemotherapy
leads to a relative reduction in the risk of recurrence of approximately 30% on average, which
translates into an absolute benefit in the rate of
freedom from recurrence of up to 5 percentage
points.12,13 Many patients with estrogen-receptor–
positive breast cancer would therefore be overtreated with chemotherapy on the basis of clinicopathologic features alone, since most would
have been adequately treated with endocrine
therapy alone.14
Previous studies have shown that a 21-gene
2006
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expression assay provides additional prognostic
information independent of clinicopathologic
features15 and also predicts benefit from adjuvant chemotherapy in estrogen-receptor–positive
disease.16,17 Prospective validation was performed
with the use of archival tumor specimens from
completed studies that used a prospective–retrospective design.18 However, validation in prospectively conducted studies provides the highest
level of evidence supporting the clinical validity
and ultimately the clinical usefulness of a new
biomarker.19,20
Here we report the results of a prospectively
conducted clinical trial, the Trial Assigning Individualized Options for Treatment (TAILORx).
This trial was designed to further validate and
refine the clinical usefulness of the 21-gene assay (Oncotype DX Recurrence Score, Genomic
Health) in a specified low-risk cohort of women
with hormone-receptor–positive, HER2-negative,
axillary node–negative invasive breast cancer.

Me thods
Study Patients

The study included women 18 to 75 years of age
with axillary node–negative invasive breast cancer that was estrogen-receptor–positive or progesterone-receptor–positive (or both) and that
did not overexpress HER2. Patients had to meet
National Comprehensive Cancer Network guidelines for the recommendation of adjuvant chemotherapy,21 including a primary tumor size of 1.1 to
5.0 cm in the greatest dimension for a tumor of
any grade or a size of 0.6 to 1.0 cm in the greatest dimension for a tumor of intermediate or
high histologic grade or nuclear grade (or both).
Other eligibility criteria included an Eastern
Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a scale from
0 to 5, with higher numbers indicating greater
disability; a score of 0 indicates no symptoms,
and a score of 1 mild symptoms) and normal
hematologic, bone marrow, hepatic, renal, pulmonary, and cardiac function. Patients with
HER2-overexpressing disease were excluded because most have a high risk of recurrence14 and
because such patients benefit from adjuvant
HER2-directed therapy plus chemotherapy.22
Study Protocol

This prospective clinical trial was sponsored by
the National Cancer Institute (NCI), was coordi-

nejm.org

November 19, 2015

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on January 19, 2016. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

21-Gene Expression Assay in Breast Cancer

nated by the ECOG and subsequently the ECOG–
ACRIN Cancer Research Group, and included
other participating NCI-sponsored groups. Patients were required to provide written informed
consent, including willingness to have treatment
assigned or randomly assigned on the basis of the
genetic-assay results indicating the risk of recurrence.
All the patients had an Oncotype DX Recurrence Score, a reverse-transcriptase–polymerasechain-reaction 21-gene assay performed on RNA
extracted from formalin-fixed paraffin-embedded tissue, performed in a central laboratory
(Genomic Health).15 The recurrence scores range
from 0 to 100, with higher scores indicating a
greater risk of recurrence. Patients with a score
of 0 to 10 were assigned to receive endocrine
therapy alone, and those with a score of 26 or
higher were assigned to receive chemotherapy plus
endocrine therapy. Prior studies indicated that
patients with a score of less than 11 had a favorable prognosis with endocrine therapy alone15
and also that patients with a score of 26 to 30 or
higher derived substantially greater benefit from
adjuvant chemotherapy.16,17 Patients with a midrange score of 11 to 25 were randomly assigned
to receive either chemotherapy plus endocrine
therapy or endocrine therapy alone because the
benefits of chemotherapy were uncertain in this
group, yet the risk of recurrence was high enough
to suggest that chemotherapy might be beneficial.
To minimize the potential for undertreatment
of the participants enrolled in our trial, the recurrence-score ranges used in our study differed
from those that were originally defined as low
(≤10 in our study vs. <18 in the original definition), intermediate (11 to 25 vs. 18 to 30), and
high (≥26 vs. ≥31).14 The recurrence-score strata
derived for the trial were based on prior studies
that indicated that the risk of recurrence of breast
cancer at a distant site at 10 years after diagnosis
and a 5-year course of tamoxifen could be as
high as 10% among patients with a score of 11
(point estimate, 7%; 95% confidence interval [CI],
5 to 10) and up to 20% among those with a score
of 25 (point estimate, 16%; 95% CI, 13 to 20),15
indicating a risk that was substantial enough for
a recommendation of adjuvant chemotherapy in
patients with a score of 11 or higher.14

some changes recommended by the coauthors
and Genomic Health. Data were collected by the
Cancer Trials Support Unit and the ECOG–
ACRIN Cancer Research Group Coordinating
Center. All the authors vouch for the accuracy
and completeness of the data and analyses presented and for the adherence of the study to the
protocol, which is available with the full text of
this article at NEJM.org. No commercial support
was involved in the planning or execution of the
study, although the genomic test used is commercially available.
Study End Points

The standardized definitions for efficacy end
points (STEEP) criteria were used for the endpoint definitions.23 The primary trial end point
was a time-to-event analysis of the rate of survival free from invasive cancer, with an invasivecancer event defined as the first event of recurrence of ipsilateral breast tumor, local recurrence,
regional recurrence, distant recurrence, contralateral second primary invasive cancer, second
primary nonbreast invasive cancer (excluding
nonmelanoma skin cancer), or death without
evidence of recurrence (which corresponds to
the STEEP definition of invasive disease–free
survival).
Secondary end points included time-to-event
analyses of the freedom from the recurrence of
breast cancer at a distant site, with an event of
breast cancer at a distant site defined as the first
event of distant recurrence of breast cancer or
death with distant recurrence, if death was the
first manifestation of distant recurrence (which
corresponds to the STEEP definition of distant
recurrence–free interval); freedom from any recurrence, with recurrence defined as the first
recurrence of breast cancer at any site (including
ipsilateral breast cancer, local or regional recurrence, or distant recurrence) or death with recurrence, if death was the first manifestation of
recurrence (which corresponds to the STEEP
definition of recurrence-free interval); and the
overall survival rate, which was defined as the
proportion of patients who did not die (from any
cause). End-point assessments that were consistent with standard of care at regular intervals
were specified in the protocol, and copies of
source documents supporting each event were
Study Oversight
reviewed and corroborated by one of the coauThe manuscript was written by the first author; thors who did not have knowledge of the study
the final version of the manuscript incorporated group or the recurrence-score information.
n engl j med 373;21

nejm.org

November 19, 2015

2007

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on January 19, 2016. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

Statistical Analysis

The overall sample size in all the risk strata defined according to recurrence score was driven
by the need to include a sufficient number of
patients with a score of 11 to 25 (midrange risk)
in order to test the noninferiority of endocrine
therapy alone versus chemotherapy plus endocrine therapy. At the fourth planned interim
analysis held on March 20, 2015, the ECOG–
ACRIN data and safety monitoring committee
recommended that the results of the low-risk
group be released and that follow-up in the randomized midrange-risk stratum and the nonrandomized high-risk stratum continue as planned.
Although there was no specific enrollment goal
for the low-risk group, the large sample provided
the opportunity to estimate 5-year event rates
accurately.
Statistical comparisons of baseline characteristics were calculated with the use of the chisquare test for categorical variables and the
Wilcoxon test and Student’s t-test for continuous
variables. Tumor size in the greatest dimension,
histologic grade of the tumor, and expression of
estrogen receptor, progesterone receptor, and
HER2 were determined locally and reported by
the participating site.
Event-free rates were estimated with the use
of the Kaplan–Meier method, with confidence
intervals computed with the use of the log–log
transformation and Greenwood’s variance. The
data-cutoff date for the results presented here
was July 29, 2015.

R e sult s

2008

of
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patients with tumors associated with a recurrence score of 0 to 10 (low-risk cohort) — as
compared with the characteristics of the patients
who had a score of 11 to 25 (midrange-risk cohort). There were no significant differences in
tumor size between these two cohorts. There
was a similar distribution of intermediate-grade
tumors (59% in the low-risk cohort and 57% in
the midrange-risk cohort), although there was a
significant difference in the distribution of grade,
including low-grade tumors (34% vs. 29%) and
high-grade tumors (7% vs. 14%) (P<0.001 for
both comparisons). There were also significant
but numerically modest differences between the
low-risk cohort and the midrange-risk cohort with
regard to age (median, 58 years vs. 55 years),
menopausal status (postmenopausal status, 70%
vs. 64%), progesterone-receptor expression (progesterone-receptor–positive, 98% vs. 92%), and
type of primary surgery (lumpectomy, 68% vs.
72%) (P<0.001 for all comparisons by the chisquare test).
Adjuvant Therapy

In the low-risk cohort of 1626 patients, endocrine therapy included an aromatase inhibitor in
963 patients (59%), tamoxifen in 560 (34%), sequential tamoxifen followed by aromatase-inhibitor therapy in 13 (1%), ovarian-function suppression in 44 (3%), or other or unknown therapy in
46 (3%). Although the protocol specified that no
chemotherapy be given if the recurrence score
was 0 to 10, a total of 6 patients received adjuvant chemotherapy (1 of whom had a recurrence
despite adjuvant chemotherapy).

Characteristics of the Patients

Event Rates at 5 Years

Between April 7, 2006, and October 6, 2010, we
enrolled 10,273 patients in the trial, of whom
10,253 were eligible to participate. A total of
1629 patients (1626 of whom were eligible
[15.9% of the total eligible population]) had a
recurrence score of 0 to 10 (indicating low risk),
6907 (6897 of whom were eligible [67.3% of the
total eligible population]) had a score of 11 to 25
(indicating midrange risk), and 1736 (1730 of
whom were eligible [16.9% of the total eligible
population]) had a score of 26 or higher (indicating high risk). The median follow-up in the lowrisk cohort was 69 months.
Table 1 shows the characteristics of the study
population that was included in this analysis —

In the cohort of patients with a recurrence score
of 0 to 10, there were 88 events of either invasive
cancer or death and 30 deaths reported within
5 years after study entry. The first event in the
analysis of survival free from invasive disease
was local or regional recurrence (or both) in 8 patients, distant recurrence in 10, invasive cancer
of the opposite breast in 15, other invasive new
primary cancer in 43, and death without another
event in 12. The Kaplan–Meier estimates for
each end point examined are shown in Figure 1.
In this cohort, the rate of invasive disease–
free survival at 5 years was 93.8% (95% CI, 92.4
to 94.9). The rate of freedom from recurrence of
breast cancer at a distant site at 5 years was
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Table 1. Characteristics of the Patients at Baseline, According to Recurrence-Score Cohort.*

Characteristic

Recurrence Score,
0–10
(N = 1626)

Recurrence Score,
11–25
(N = 6897)

P Value

15.9

67.3

—

58 (50–64)

55 (48–62)

<0.001

57±9

55±9

<0.001

Percent of all enrolled patients
Age
Median (interquartile range) — yr
Mean — yr
Distribution — no. (%)

<0.001

≤40 yr

58 (4)

319 (5)

41–50 yr

372 (23)

1964 (28)

51–60 yr

566 (35)

2503 (36)

61–70 yr

519 (32)

1811 (26)

>70 yr

111 (7)

300 (4)

Menopausal status — no./total no. (%)

<0.001

Postmenopausal

1143/1623 (70)

4396/6873 (64)

Premenopausal

480/1623 (30)

2477/6873 (36)

1.5 (1.2–2.0)

1.5 (1.2–2.0)

0.31

1.74±0.77

1.71±0.79

0.23

Tumor size in the greatest dimension
Median (interquartile range) — cm
Mean — cm
Distribution — no./total no. (%)

0.42

<1.0 cm

128/1626 (8)

568/6883 (8)

1.0–1.9 cm

993/1626 (61)

4270/6883 (62)

2.0–2.9 cm

366/1626 (23)

1543/6883 (22)

3.0–3.9 cm

104/1626 (6)

358/6883 (5)

35/1626 (2)

144/6883 (2)

≥4.0 cm
Histologic grade of tumor — no./total no. (%)

<0.001

Low

530/1578 (34)

1941/6665 (29)

Intermediate

937/1578 (59)

3812/6665 (57)

High

111/1578 (7)

912/6665 (14)

Estrogen-receptor expression — no./total no. (%)
Negative

0.28
5/1626 (<1)

Positive

10/6885 (<1)

1621/1626 (>99)

6875/6885 (>99)

Negative

28/1590 (2)

528/6752 (8)

Positive

1562/1590 (98)

6224/6752 (92)

Lumpectomy

1106/1626 (68)

4986/6885 (72)

Mastectomy

520/1626 (32)

1899/6885 (28)

Progesterone-receptor expression — no./total no. (%)

<0.001

Primary surgery — no./total no. (%)

<0.001

*	Plus–minus values are means ±SD. Patients were assigned to a risk cohort on the basis of the recurrence score on the
21-gene assay. Scores range from 0 to 100, with higher scores indicating a greater risk of recurrence. Patients with a
score of 0 to 10 were included in the low-risk cohort and were assigned to receive endocrine therapy alone. Patients
with a score of 11 to 25 were included in the midrange-risk cohort and were randomly assigned to receive either chemotherapy plus endocrine therapy or endocrine therapy alone. (Patients with a score of ≥26 were assigned to receive
chemotherapy plus endocrine therapy and were not included in this analysis.) Statistical comparisons were calculated
with the use of the chi-square test for categorical variables and the Wilcoxon test and Student’s t-test for continuous
variables. Tumor size in the greatest dimension, histologic grade of the tumor, and expression of estrogen receptor,
progesterone receptor, and HER2 were determined locally and reported by the participating site. Percentages may not
total 100 because of rounding.
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Figure 1. Kaplan–Meier Estimates in the Analyses of Invasive Disease–free Survival, Freedom from Recurrence of Breast Cancer at a Distant
Site, Freedom from Recurrence at Any Site, and Overall Survival.
A total of 1626 patients with a recurrence score of 0 to 10 (on a scale from 0 to 100, with higher scores indicating a greater risk of recurrence)
were included in the analyses. In the time-to-event analysis of invasive disease–free survival, Panel A shows the probability of freedom
from the first event of recurrence of ipsilateral breast tumor, local recurrence, regional recurrence, distant recurrence, contralateral second
primary invasive cancer, second primary nonbreast invasive cancer (excluding nonmelanoma skin cancer), or death without evidence of
recurrence (which corresponds to the standardized definitions for efficacy end points [STEEP]23 definition of invasive disease–free survival).
In the time-to-event analysis of freedom from the recurrence of breast cancer at a distant site, Panel B shows the probability of freedom
from the first event of distant recurrence of breast cancer or death with distant recurrence, if death was the first manifestation of distant recurrence (which corresponds to the STEEP definition of distant recurrence–free interval). In the time-to-event analysis of freedom from recurrence at any site, Panel C shows the probability of freedom from the first event of recurrence of breast cancer (ipsilateral breast cancer,
local or regional recurrence, or distant recurrence) or the date of death with recurrence, if death was the first manifestation of recurrence
(which corresponds to the STEEP definition of recurrence-free interval). Panel D shows the probability of overall survival in the time-toevent analysis. In each panel, dashed lines indicate 95% confidence intervals and the insets show the same data on an enlarged y axis.

99.3% (95% CI, 98.7 to 99.6), the rate of freedom
from recurrence at 5 years was 98.7% (95% CI,
97.9 to 99.2), and the rate of overall survival at
5 years was 98.0% (95% CI, 97.1 to 98.6).

dimension), histologic grade (high vs. intermediate vs. low), and surgery type (mastectomy vs.
lumpectomy), only histologic grade showed a
significant association with the rate of freedom
from recurrence. However, histologic grade did
Multivariate Analysis and Effect of Tumor
not show a significant association with the rate
Grade and Age of the Patient
of invasive disease–free survival or the rate of
In a multivariate analysis that included age (≤50 freedom from distant recurrence (Table 2). Reyears vs. 51 to 60 years vs. 61 to 75 years), tumor currence rates were very low regardless of histosize (2.1 to 5.0 cm vs. ≤2 cm in the greatest logic grade (Table 3).
2010
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Discussion

Table 2. Multivariate Analysis.*

We performed a prospective validation study of a
21-gene assay in patients with hormone-receptor–
positive, HER2-negative breast cancer who had a
low risk of recurrence according to clinicopathologic features but who nevertheless met established clinical guidelines for the recommendation or consideration of adjuvant chemotherapy.
In patients who were found to have a low risk of
recurrence on the basis of genetic-assay results
and who were thus assigned to receive endocrine
therapy alone, the risk of the recurrence of breast
cancer at a distant site was less than 1% and the
risk of any recurrence was less than 2% at 5 years.
Recurrence events were uncommon regardless
of histologic grade and were not significantly
affected by younger age at diagnosis. In fact, in
this low-risk population, the rate of recurrence
events at 5 years was far exceeded by the rates of
second primary breast cancers, other second
primary-cancer events, and deaths from other
causes, which resulted in a rate of invasive disease–free survival that was nearly 5 percentage
points lower than the rate of freedom from recurrence (93.8% vs. 98.7%).
Although adjuvant chemotherapy reduced the
risk of distant recurrence and local–regional recurrence in the Early Breast Cancer Trialists
meta-analysis, there was only a marginal effect
in reducing the risk of contralateral breast cancer and no effect on the risk of second primary
cancers or on nonbreast-cancer mortality after
15 years of follow-up in nearly 29,000 patients
who had been randomly assigned to receive either
chemotherapy or no chemotherapy.12 The low rate
of distant recurrence observed in this prospective study is consistent with the rate observed at
5 years in the original prospective–retrospective
validation study involving patients with a low
recurrence score of less than 18 (2.1%; 95% CI,
0.6 to 3.7).14,15
The current prospectively conducted study supports the use of the 21-gene assay to spare the use
of chemotherapy in patients who otherwise would
be recommended to receive it on the basis of
clinicopathologic features. These findings provide
additional evidence supporting expert-derived
clinical practice guidelines that recommend the
use of this assay in patients with hormone-
receptor–positive, axillary node–negative invasive
breast cancer.21,24 Although this study clearly
identifies patients who do not benefit from adn engl j med 373;21

End Point

Hazard Ratio (95% CI) P Value

Recurrence, second primary breast cancer,
second primary nonbreast
invasive cancer, or death without
recurrence of cancer
Tumor grade

0.13

Intermediate vs. low

1.56 (0.92–2.63)

High vs. low

2.05 (0.92–4.55)

Tumor size >2 cm vs. ≤2 cm

1.17 (0.71–1.92)

Age
51–60 yr vs. ≤50 yr
61–75 yr vs. ≤50 yr
Lumpectomy vs. mastectomy

0.54
0.07

0.87 (0.46–1.64)
1.53 (0.87–2.70)
0.63 (0.38–1.06)

0.07

Tumor grade of high or intermediate
vs. low†

3.83 (0.48–30.69)

0.14

Tumor size >2 cm vs. ≤2 cm

1.55 (0.38–6.31)

0.55

Recurrence at a distant site

Age

0.27

51–60 yr vs. ≤50 yr

1.28 (0.12–4.22)

61–75 yr vs. ≤50 yr

3.49 (0.42–29.16)

Lumpectomy vs. mastectomy

0.57 (0.12–2.82)

0.47

Recurrence at any site
Tumor grade

0.02

Intermediate vs. low

8.07 (1.06–61.45)

High vs. low

4.73 (0.29–76.42)

Tumor size >2 vs. ≤2 cm

1.06 (0.33–3.33)

Age

0.33

51–60 yr vs. ≤50 yr

0.41 (0.10–1.73)

61–75 yr vs. ≤50 yr

0.98 (0.32–3.02)

Lumpectomy vs. mastectomy

0.93

0.93 (0.32–2.71)

0.89

*	Data from 1578 of 1626 patients with a recurrence score of 0 to 10 were included in these analyses. Data from 48 patients for whom the histologic grade
of the tumor was not reported were excluded from these analyses.
†	Data from patients with a high tumor grade and those with an intermediate
tumor grade were combined for the analysis of freedom from the recurrence
of breast cancer at a distant site because of the small number of events.

juvant chemotherapy, only 16% of the enrolled
patients had a recurrence score of 10 or less.
Approximately 67% of the patients enrolled in
the trial had a midrange score of 11 to 25 and
were randomly assigned to receive chemotherapy
plus endocrine therapy or endocrine therapy
alone. Continued follow-up is required in order
to determine the effect of chemotherapy in this
larger group of patients.
Late recurrence that occurs after 5 years accounts for approximately one half of all distant
recurrences in patients with estrogen-receptor–
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Table 3. Event Rates at 5 Years, According to Histologic Grade.*

Tumor Grade
All grades

Invasive Disease–free
Survival
(95% CI)

Freedom from
Distant Recurrence
(95% CI)

Freedom from
Any Recurrence
(95% CI)

Overall Survival
(95% CI)

93.8 (92.4–94.9)

99.3 (98.7–99.6)

98.7 (97.9–99.2)

98.0 (97.1–98.6)

Low grade

95.8 (93.5–97.3)

99.8 (98.3–100)

99.8 (98.3–100)

98.7 (97.0–99.4)

Intermediate grade

93.6 (91.7–95.1)

99.0 (98.0–99.5)

98.2 (97.0–99.0)

97.9 (96.8–98.7)

High grade

91.3 (83.9–95.4)

100 (NC–NC)

98.7 (91.1–99.8)

97.3 (91.9–99.1)

*	The analyses for all tumor grades included data from all 1626 patients who had a recurrence score of 0 to 10, including
the 48 patients with the tumor grade not reported. A total of 530 patients were included in the analyses for low-grade
tumor, 937 in the analyses for intermediate-grade tumor, and 111 in the analyses for high-grade tumor. In the time-toevent analysis of invasive disease–free survival (primary end point), the rate indicates freedom from the first event of
recurrence of ipsilateral breast tumor, local recurrence, regional recurrence, distant recurrence, contralateral second primary invasive cancer, second primary nonbreast invasive cancer (excluding nonmelanoma skin cancer), or death without evidence of recurrence (which corresponds to the standardized definitions for efficacy end points [STEEP]23 definition of invasive disease–free survival). In the time-to-event analysis of recurrence of breast cancer at a distant site, the
rate indicates freedom from the first event of distant recurrence of breast cancer or death with distant recurrence, if
death was the first manifestation of distant recurrence (which corresponds to the STEEP distant recurrence–free interval definition). In the time-to-event analysis of freedom from any recurrence, the rate indicates freedom from the first
recurrence of breast cancer (ipsilateral breast cancer, local or regional recurrence, or distant recurrence) or the date of
death with recurrence, if death was the first manifestation of recurrence (which corresponds to the STEEP recurrencefree interval definition). NC denotes not calculated.

positive, HER2-negative breast cancer.25 There
are several prognostic gene-expression assays
for breast cancer,26 some of which are more accurately prognostic for late recurrence than others.27,28 However, the 21-gene assay predicts
benefit from adjuvant chemotherapy,16,17 and
chemotherapy prevents primarily early recurrences within 5 years after diagnosis.8 Therefore,
although more recurrences are expected with
longer follow-up, it is unclear whether these recurrences would have been prevented by the
early administration of adjuvant chemotherapy.
Extended adjuvant endocrine therapy beyond 5
years is effective in preventing late recurrence
and may be considered when the treating clinician and the patient perceive a favorable benefit–
risk ratio.29,30
The distribution of recurrence scores observed in this prospective trial differs from the
distribution that was initially projected on the
basis of observations in a prior prospective–retrospective validation study, which included 27%
of patients with a score of 0 to 10, 43% with a
score of 11 to 25, and 30% with a score of 26 or
higher.14,16 This finding may be due to clinicians
selecting patients for this study in whom there
was therapeutic equipoise regarding the benefit
of chemotherapy, which is reflected by the large
proportion of patients who had tumors of 1.1 to
2.0 cm in the greatest dimension or tumors of
intermediate histologic grade. However, the dis2012

n engl j med 373;21

tribution of scores that was observed in this
trial is similar to the distribution observed by
the commercial laboratory during the same time
period in which the study was conducted (score
of 0 to 10 in 18% of patients, score of 11 to 25
in 62%, and score of ≥26 in 20%; Shak S, Genomic Health: personal communication). This
finding indicates that the distribution of risk
groups in the trial reflects clinical practice in
the community and supports the generalizability
of the study findings.
The RASTER (Microarray Prognostics in
Breast Cancer) study was a prospective validation
study that evaluated a different multigene assay,
the 70-gene signature, in 427 patients with axillary node–negative breast cancer.31 The 5-year
rate of freedom from distant recurrence was
97.0% among patients with a low-risk signature
on the 70-gene assay (51% of all patients) and
91.7% among those with a high-risk signature
(49% of all patients).32 Decisions regarding adjuvant systemic treatment were based on the
Dutch Institute for Healthcare Improvement
2004 guidelines, the 70-gene signature, and doctors’ and patients’ preferences. Adjuvant chemotherapy was given to 169 patients (81%) with a
high-risk signature and in 33 (15%) with a lowrisk signature. The outcomes observed in the
RASTER study may therefore have been attributable, at least in part, to chemotherapy administered in selected patients in the low-risk group.
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The MINDACT (Microarray in Node Negative
Disease May Avoid Chemotherapy) trial is a prospective trial in which patients were randomly
assigned to receive chemotherapy or no chemotherapy on the basis of clinical criteria or the
70-gene signature; enrollment has been completed and follow-up is ongoing.33 Although the
results of the MINDACT trial are likely to provide important information, gene-expression assays bring added value by providing complementary predictive information that is independent
of and does not correlate with clinicopathologic
features in selected patients for whom this information may be clinically useful.34,35 Other
ongoing trials (RxPONDER36 and OPTIMA37) are
evaluating whether adjuvant chemotherapy is
beneficial in patients with hormone-receptor–
positive, HER2-negative breast cancer with positive axillary lymph nodes and a recurrence score
of 25 or less.
In conclusion, this prospective study involving
uniformly treated patients with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer supports the clinical validity
of the 21-gene assay in identifying patients who
may be safely spared adjuvant chemotherapy.
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